FDA Drug Recalls in the News

Vioxx® Removed from the Market

Merck has withdrawn Vioxx®, its arthritis and acute pain medication, from the market in the wake of a clinical study showing a significant increased risk in heart attacks and strokes after Vioxx® use. Gancedo & Nieves, L.L.P. are experts in handling Vioxx® cases. The firm represents many individuals who have been injured by Vioxx®.
click here for complete article >>

The How and Why of the Rezulin® Story

Every year the FDA performs drug studies and recalls those that appear dangerous. When a drug is responsible for the deaths of 63 people over the course of almost two and a half years, questions about blame are inevitable. In the case of Rezulin®, both the FDA and the drug's manufacturer, Warner-Lambert, failed to recall the drug despite cascading evidence of its deadliness. How and why this occurred is examined by Pulitzer-prize winning journalist David Willman in his article.
click here for complete article >>

Rezulin®: A Deadly History

The diabetes drug Rezulin® has a history fraught with controversy. From its initial submission for review through its time on the market, Rezulin® was suspected to cause liver damage and other health problems. Despite the findings of researchers and numerous reported cases of liver failure among those taking the drug, the FDA allowed Rezulin® first to be approved and then to remain on the market -- even once its propensity to cause adverse health effects was well-known.
click here for complete article >>

Former Proponent Calls for Rezulin's Withdrawal

Medical Officer Robert I. Misbin, formerly one of Rezulin's biggest advocates, changed his position in February 2000. While he originally supported the drug as a good option for patients with diabetes, reports of sudden, often fatal, liver failure spawned his reversal of opinion. In an email to his colleagues, Misbin recommended that the FDA add Rezulin® to its list of drug recalls.
click here for complete article >>

FDA Threatens to Fire Rezulin® Opponent

In February of 2000, Dr. Robert Misbin spoke out against the diet drug Rezulin® in an e-mail to his boss; in March, new emails threatened his dismissal. Misbin criticized the FDA for allowing Rezulin® to stay on the market despite its potential dangers. Now it seems that his push for action may rob him of his job.
click here for complete article >>

Rezulin® Recalled At Last

Rezulin®, a diabetes drug linked to at least 63 deaths from liver failure, was recalled on March 21, 2000. The drug, originally "fast-tracked" for approval by the FDA, was not withdrawn until nearly two and half years after the first reported Rezulin-related death. Two newer diabetes drugs were found to be significantly safer, and Rezulin® was deemed to be the most dangerous diabetes drug available by Dr. David J. Graham, senior epidemiologist for the FDA. For more information about drug recalls use the link below.
click here for complete article >>